Cortoss to target vertebral compression fractures:
This article was originally published in Clinica
Executive Summary
Orthovita says that it plans to submit to European regulatory authorities by the end of 2002 data from a study that is assessing its Cortoss biomaterial as a means of repairing vertebral compression fractures. Cortoss, a synthetic cortical bone void filler, has been on sale in Europe since January 2002 for the fixation of bone screws used in patients with weak bone caused by osteoporosis. The new study is evaluating the ability of the product to provide pain relief by providing new stability to the fractured vertebra, says the Malvern, Pennsylvania firm.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.